AI brief of an SEC Form 8-K · Aurinia Pharmaceuticals Inc. (AUPH)

Aurinia raises 2026 revenue guidance to $325 million-$330 million; Q3 revenue up 14%

Positive Impact 4 of 5 earnings Written later

Aurinia reported third-quarter 2026 total revenue of $83.7 million, up 14% from a year earlier, while net income and diluted earnings per share were flat at $31.7 million and $0.23. The company raised its 2026 total revenue guidance to $325 million to $330 million and narrowed its net product sales guidance to $310 million to $315 million.

Key points

  • Q3 2026 total revenue was $83.7 million, up 14% from $73.5 million; net product sales of LUPKYNIS were $79.4 million.
  • Q3 net income was $31.7 million, flat year over year; nine-month net income rose 35% to $103.5 million.
  • 2026 total revenue guidance raised from $315 million-$325 million to $325 million-$330 million.
  • As of September 30, 2026, cash, cash equivalents, restricted cash and investments totaled $486.9 million.

The filing

CompanyAurinia Pharmaceuticals Inc. (AUPH)
Form8-K, current report
Filed with the SECOct 30, 2026, 8:03 AM ET
Accession number0001600620-26-000074

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.